DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DBD - US2536512021 - Common Stock
69.195 USD
+0.53 (+0.78%)
We assign a fundamental rating of 4 out of 10 to DBD. DBD was compared to 35 industry peers in the Technology Hardware, Storage & Peripherals industry. Both the profitability and the financial health of DBD get a neutral evaluation. Nothing too spectacular is happening here. DBD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
DBD had a positive operating cash flow in the past year.
In the past 5 years DBD reported 4 times negative net income.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of DBD (1.36%) is better than 68.57% of its industry peers.
With a decent Return On Equity value of 4.57%, DBD is doing good in the industry, outperforming 80.00% of the companies in the same industry.
With a decent Return On Invested Capital value of 8.85%, DBD is doing good in the industry, outperforming 71.43% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 16.06%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.85%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
DBD has a Profit Margin of 1.37%. This is in the better half of the industry: DBD outperforms 68.57% of its industry peers.
Looking at the Operating Margin, with a value of 7.47%, DBD is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
DBD's Operating Margin has improved in the last couple of years.
DBD has a Gross Margin of 25.48%. This is in the lower half of the industry: DBD underperforms 60.00% of its industry peers.
DBD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DBD is destroying value.
Compared to 1 year ago, DBD has about the same amount of shares outstanding.
The number of shares outstanding for DBD has been reduced compared to 5 years ago.
The debt/assets ratio for DBD has been reduced compared to a year ago.
2.2 Solvency
DBD has an Altman-Z score of 1.96. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.96, DBD is in line with its industry, outperforming 57.14% of the companies in the same industry.
The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
DBD has a Debt to FCF ratio of 3.71. This is in the better half of the industry: DBD outperforms 68.57% of its industry peers.
A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
DBD's Debt to Equity ratio of 0.84 is in line compared to the rest of the industry. DBD outperforms 45.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.96 |
ROIC/WACC0.94
WACC9.4%
2.3 Liquidity
A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
DBD has a Current ratio (1.36) which is comparable to the rest of the industry.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.89, DBD is in line with its industry, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
DBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.07%.
The Earnings Per Share has been growing by 69.69% on average over the past years. This is a very strong growth
Looking at the last year, DBD shows a decrease in Revenue. The Revenue has decreased by -2.86% in the last year.
Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.21% on average per year.
Based on estimates for the next years, DBD will show a small growth in Revenue. The Revenue will grow by 2.51% on average per year.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.91, the valuation of DBD can be described as rather expensive.
Based on the Price/Earnings ratio, DBD is valued a bit cheaper than 74.29% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.25, DBD is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 14.08, the valuation of DBD can be described as correct.
DBD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 71.43% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, DBD is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.91 | ||
| Fwd PE | 14.08 |
4.2 Price Multiples
94.29% of the companies in the same industry are more expensive than DBD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, DBD is valued cheaply inside the industry as 82.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.86 | ||
| EV/EBITDA | 7.59 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DBD's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.14
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%
5. Dividend
5.1 Amount
DBD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:DBD (1/13/2026, 11:59:36 AM)
69.195
+0.53 (+0.78%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.4%
Inst Owner Change0.11%
Ins Owners1.81%
Ins Owner Change0%
Market Cap2.48B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (16.45%)
Short Float %2.22%
Short Ratio3.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)0%
PT rev (3m)4.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.72%
EPS NY rev (1m)0%
EPS NY rev (3m)12.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.91 | ||
| Fwd PE | 14.08 | ||
| P/S | 0.67 | ||
| P/FCF | 9.86 | ||
| P/OCF | 8.88 | ||
| P/B | 2.24 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.59 |
EPS(TTM)3.66
EY5.29%
EPS(NY)4.92
Fwd EY7.1%
FCF(TTM)7.01
FCFY10.14%
OCF(TTM)7.79
OCFY11.26%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.14
PEG (5Y)N/A
Graham Number50.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.96 |
F-Score7
WACC9.4%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
Can you provide the valuation status for DIEBOLD NIXDORF INC?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.
What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 5 / 10.
How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.